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Abstract
Malignant gliomas remain the most devastating childhood and adult tumors of the central nervous system. Al-
though adult and pediatric gliomas are histologically indistinguishable, they differ in location, behavior, and molec-
ular characteristics. This implies that the molecular pathways and pathophysiology of malignant gliomagenesis in
these two populations are distinct. Such differences between adult and pediatric gliomas may predict different
therapeutic responses. Therefore, accurate genetically engineered models of adult and pediatric gliomas may help
understand the biology of these tumors and evaluate therapeutic agents in preclinical studies. It has been pro-
posed that gliomas arise from the subventricular zone in mice during development. Here, we demonstrate that,
in adult mice, gliomas may arise not only when injected in the subventricular zone but also when injected in the
cortex and cerebellum. Our work demonstrates a versatile and highly reproducible adult mouse model of glioma,
which can be easily incorporated into preclinical studies.
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Introduction
Malignant gliomas constitute a genetically and histologically hetero-
geneous group of tumors associated with significant mortality and
morbidity [1]. These tumors occur in children; however, they are
far more prevalent in adults. In adults, high-grade gliomas are com-
posed of anaplastic astrocytoma (AA), anaplastic oligodendroglioma,
and glioblastoma multiforme (GBM). They can also exist as mixed
lineage tumors, most commonly as anaplastic oligoastrocytoma [1].
In general, malignant gliomas progress rapidly and are resistant to
therapy [2]. The survival rate for GBM is approximately 1 year
[2,3], 2 years for AA, and 5 years for anaplastic oligodendroglioma
[4]. Although the bulk of research in glioma biology relies on valu-
able tools such as passaged cell lines and xenograft models, there is
growing evidence that these conditions do not represent a compre-
hensive scope of the cellular complexity human gliomas [5]. Brain
tumors are diagnosed principally based on histologic characteristics,
with less attention paid to the several known molecular alterations
that occur commonly in gliomas, possibly contributing to the poor
survival of GBM patients. Although the current histological diagnos-
tic criteria provide good prognostic information, they do not inform
optimum therapy. Illustrating this point, as standard of care, all pa-
tients with the diagnosis of high-grade gliomas are currently treated
identically without consideration of the molecular variables that may
impact treatment.
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During the last two decades, a number of groups have sought to
identify molecular subtypes of gliomas, an undertaking that remains
a critical challenge for glioma biologists [2,6]. Genetic alterations
found in adult gliomas have generally been divided into two groups.
The first group contains genes that are related to growth factors, their
receptors, and signal transduction pathways. These include anomalies
of platelet-derived growth factor receptors (PDGFR1/2) [7–10],
epidermal growth factor receptor [6,11,12], fibroblast growth factor
receptor [13,14], ciliary neurotrophic factor [15], and hepatocyte
growth factor/scatter factor [16]. The second group encompasses
genes implicated in cell cycle regulation, such as the INK4a-ARF
locus, which is altered in 60% of GBM [17], and the RB gene, which
is altered in 33% of GBM [18]. Mutations in tumor suppressors
TP53 and PTEN are also common genetic alterations in human
GBM [19]. In addition to the classification based on basic molecular
alterations, GBM can be further subdivided into primary GBM,
which arise de novo, and secondary glioblastomas that progress from
lower-grade gliomas and likely constitute a highly heterogeneous
group [2].
Our increased understanding of the diverse alterations in human
gliomas and the potential significance of these alterations to thera-
peutic responses have increased the need for additional genetically
engineered mouse models. Data obtained from preclinical evaluations
of therapies using new genetically engineered mouse models that re-
flect the heterogeneity of human disease may open new treatment
avenues. Furthermore, such studies may help to identify differences
in response to therapeutic agents between the various subgroups of
glioma and to facilitate the design of individualized therapeutic ap-
proaches based not only on histological characteristics but also on ge-
netic alterations and tumor location.
To study glioma development, we have modeled gliomas using the
RCAS/tv-a system to initiate tumors in newborn mice with known
glioma oncogenic drivers. This model system allows somatic gene
transfer of selected oncogenes, such as PDGF and Kras, into targeted
brain cells engineered to express the tv-a receptor. These transgenic
tv-a mice can then be crossed onto various genetic backgrounds to
model the effects of genetic aberrations such as tumor suppressor loss
on glioma formation and response to therapy. Using this model, we
have observed that oncogenes such as Kras and PDGF produce glio-
mas with higher grade and shorter latency in mice with Ink4a-Arf−/−
and PTEN loss backgrounds (mostly GBM) compared with wild
type mice, which develop mostly low-grade tumors [20,21]. These
studies provide important mechanistic insights into the role of spe-
cific tumor suppressor loss in PDGF- and Kras-induced pediatric gli-
omas. The short latency of high-grade glioma development in these
tumor suppressor-loss backgrounds, results in animals injected while
pups developing GBM when they are very small (∼10-15 g). This
feature of our pediatric RCAS/tv-a glioma model presents a challenge
for use of these animals in long-term treatment experiments. Because
of this limitation and the documented molecular differences between
adult and pediatric gliomas [22–24], we sought to develop an adult
glioma model using RCAS/tv-a methodology. The availability of
valid adult glioma models that more easily permit preclinical thera-
peutic studies are urgently needed and, furthermore, will facilitate
comparison of differences in the biology and therapeutic responses
between adult and pediatric gliomas.
To generate gliomas in adult mice, we stereotactically delivered
PDGFB into adult tv-a mice at various intracranial locations. We
were able to generate gliomas by overexpressing oncogenes in nestin-
and GFAP-positive cells of mice deleted for various tumor suppres-
sors. These mice represent excellent tools for dissecting the role of
location, genetic background, and cell of origin in the response to
radiation and chemotherapy in adult gliomas. Data obtained from
these studies can then be evaluated in parallel with data obtained
from pediatric preclinical studies.
Using a stereotactic technique to infect cells in different regions of
the brain in adult mice, we investigated the effect of location on the
tumor initiating ability of a given oncogene. We chose the subven-
tricular zones (SVZ), a region known to maintain central nervous
system stem cells into adulthood, the left and right hemispheres,
and the cerebellum. Our results demonstrate that PDGF-driven glio-
magenesis is possible in the SVZ, cortex, and the cerebellum, sug-
gesting that tumor-initiating cells responding to PDGF in adults
may reside in different intracerebral locations.
Materials and Methods
Mice
Ntv-a wt, Gtv-a wt, Gtv-a Ink4a−/−, Gtv-a Arf−/−, Gtv-a p53−/−,
Ntv-a p53, Ntv-a Ink4a-Arf−/− LPTEN, Ntv-a Ink4a-Arf−/− Gli-luc,
Gtv-a Ink4a-Arf−/− LPTEN mice were used at an age range of 4 to
6 weeks for all experiments. The genetic backgrounds of tv-a mice are
FVB/N, C57BL6, BALB/C, and 129. Generation of tv-a, LPTEN,
and Ink4a-Arf, p53 alleles has been described [25–28].
Cell Culture and Transfections
DF-1 cells were purchased from ATCC (Manassas, VA). Cells were
grown at 39°C according to ATCC instructions. Transfections with
RCAS-PDGFB-HA, and RCAS-CRE were performed using Fugene
6 transfection kit (no. 11814443001; Roche, Mannheim, Germany)
according to manufacturer’s protocol.
Intracranial Injections
Injections were performed using stereotactic fixation device
(Stoelting, Wood Dale, IL). Mice used for these experiments were
adult from 4 to 6.5 weeks old [29,30]. There was no significant dif-
ference in tumor latency or incidence in this age range (data not
shown). Mice were anesthetized with intraperitoneal injections of
ketamine (0.1 mg/g) and xylazine (0.02 mg/g). One microliter (for
single injections or 1:1 mixture for combined injections) of 4 ×
104 transfected DF-1 cell suspension was delivered using a 30-gauge
needle attached to a Hamilton syringe. Locations were determined
according to the instructions in the atlas [31]. Two sets of coordinates
for SVZ and right hemosphere were used. Coordinates for SVZ in-
jections were bregma 0 mm, Lat (lateral) −0.5 mm (right of midline),
and a depth −1.5 mm from the dural surface; bregma 1.7 mm, Lat
−0.5 mm, and a depth 2.5 mm. Left and right hemisphere: AP
(Anteroposterior) −2 mm posterior to bregma, Lat −0.5 mm (left or
right) depth −1 mm from dural surface; bregma 0.5 mm, Lat 2 mm,
and a depth 1 mm. Cerebellum: AP −5.5 mm from bregma. Lat
−1.5 mm (to the left), depth −1.5 mm from the dural surface. Mice
were monitored carefully and sacrificed when they displayed symp-
toms of tumor development (lethargy, head tilt).
Tissue Processing
Animals used for histological analysis were killed, and brains were
removed and fixed in 10% neutral-buffered formalin for 72 hours.
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Fixed tissues were then embedded in paraffin. Formalin-fixed, paraffin-
embedded specimens were serially sectioned and slide-mounted. The
sections were deparaffinized in histoclear (Richard-Allan Scientific,
Walldorf, Germany) and were passed through graded alcohols before
staining with a hematoxylin and eosin (H&E) reagent.
Immunohistochemistry
An automated staining processing (Discovery; Ventana Medical
Systems, Inc., Tucson, AZ) was used for immunohistochemical detec-
tion. The protocols were established at the Molecular Cytology Core
Facility and at the Brain Tumor Center, Memorial Sloan-Kettering
Cancer Center. Anti-PCNA antibodies were obtained from Dako (no.
MO879; Glostrup, Denmark), anti-Ki67 from Vector (VP-RMO4,
Burlingame, CA), and anti-pH3(Ser10) from Upstate (Lake Placid,
NY) (06-570) and were used at 1:2000, 1:200, and 1:800 dilutions
in 2% BSA in PBS correspondingly.
Bioluminescent Imaging
Mice were anesthetized with 3% isoflurane before retro-orbital injec-
tion with 75 mg/kg body weight of luciferin (Xenogen, Hopkinton,
MA). One minute after injection of the luciferin, images were acquired
for 4 minutes with the IVIS (Xenogen). A photographic image was
taken onto which the pseudocolor image representing the spatial dis-
tribution of photon count is projected. We defined a circular region of
interest between the ears and used it as a standard in all experiments.
From this region, photon counts are compared between different mice.
Magnetic Resonance Imaging
All animals were imaged with a custom-made ID 32-mm quadrature
birdcage body resonator (Stark Contrast MRI Research, Erlangen,
Germany) while anesthetized using 1.5% isoflurane (Terrell, MINRAD,
Inc, Bethlehem, PA). All images were acquired on a Bruker USR
4.7T scanner (Bruker Biospin MRI, Inc, Billerica, MA). The mouse
head was imaged in the coronal orientation using a T2-weighted fast
spin-echo rapid acquisition with relaxation enhancement sequence with
repetition time = 3.5 seconds, echo time = 50 milliseconds, rapid acqui-
sition with relaxation enhancement factor of 8, number of acquisitions =
24, field of view = 3 × 2 cm, slice thickness = 0.7 mm, with an in-plane
resolution of 117 × 156 mm. Animal breathing was monitored using an
animal physiological monitor system (SA Instruments, Stony Brook,
NY) [32].
Statistical Analysis
Kaplan-Meier survival curves have been made using GraphPad
Prism 4 (GraphPad Software, San Diego, CA) and analyzed using
log-rank (Mantel-Cox) test: *P < .05; **P < .01; ***P < .001; and
absence of star, not significant.
Results
RCAS/tv-a System Allows Generation of Adult Gliomas When
Injected in the SVZ
The RCAS/tv-a model has been a very useful and productive tool
for studying pediatric brain tumors [33–36]. During the last few years,
data from genomic studies have revealed substantial molecular differ-
ences between pediatric and adult malignant gliomas. For example, loss
of the PTEN gene and amplification epidermal growth factor receptor
are uncommon in pediatric malignant gliomas, whereas these changes
frequently occur in adults [22]. Differences in genetics can result in
diverse responses to therapy in adult and pediatric gliomas. To model
adult gliomas in mice, we delivered expression of the PDGFB gene
into the SVZ, where nestin- and GFAP-positive progenitor cells reside
in normal brain [37]. Mechanically, we stereotactically injected vector-
infected chicken fibroblasts (DF-1) producing RCAS-PDGFB into
the SVZ of adult mice from 4- to 6.5-week-old transgenic mice express-
ing the tv-a receptor on nestin-positive cells (Ntv-a mice). Survival
results demonstrated that injection of RCAS-PDGFB alone into the
SVZ of Ntv-a mice resulted in long latency to tumor formation, but
when RCAS-PDGFB was introduced into Ntv-a mice with germ line
Ink4a-Arf loss, tumor latency was decreased and tumor grade was sig-
nificantly increased (Figure 1A). Approximately 16% of Ntv-a mice
injected with RCAS-PDGFB into the SVZ developed tumors with
low-grade histologic finding, whereas when RCAS-PDGF was injected
into the SVZ of Ntv-a Ink4a-Arf−/− mice, tumor incidence was 100%
and most tumors displayed microvascular proliferation and pseudo-
palisading necrosis, histologic characteristics of human GBM (Figure 1,
B and C). Tumors generated when injected into the SVZ were mainly
located adjacent to the lateral ventricles in the frontal lobe with exten-
sion into the olfactory bulb.
Figure 1. RCAS/tv-a system allows generation of adult gliomas in
the frontal lobe, when Ntv-a cells are targeted cells in the SVZ by
PDGFB. (A) Kaplan-Meier survival curve shows that PDGFB over-
expression in the SVZ of Ntv-a wt mice induces low-grade gliomas
with low incidence compared with Ntv-a Ink4a-Arf−/− background,
which leads to GBM formation with shorter latency. All the mice
without obvious evidence of tumors were killed 235 days after in-
jection. (B) Table showing the tumor incidence (%) by PDGFB
overexpression in Ntv-a and Ntv-a Ink4a-Arf−/− backgrounds. (C)
Corresponding H&Es for A. Scale bar, 74 μm.
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Generation of Gliomas in Different Locations
Recent studies from two different groups have suggested that his-
tologically similar tumors located in different brain regions are mo-
lecularly distinct, raising the possibility that these tumors might arise
from different cells of origin [38–40]. To model the tumorigenic po-
tential of different locations in the mammalian brain, we injected
RCAS-PDGFB DF-1 producer cells in combination with RCAS-
Cre (to induce PTEN loss in mice harboring the floxed PTEN trans-
gene) in four different locations in Ntv-a Ink4a-arf−/− LPTEN mice:
1) the SVZ, 2) the right and the 3) left cerebral hemispheres, and
4) the cerebellum. Figure 2A depicts the Kaplan-Meier survival curve
of mice injected in these four different locations. Mice injected in
either the SVZ or the right or left cerebral hemispheres show similar
survival, whereas mice injected in the cerebellum exhibit significantly
longer survival compared with the other three locations. In summary,
all of the mice injected in the SVZ and the right and left cerebral
hemispheres developed tumors, whereas 83% of cerebellum-injected
mice developed tumors (Figure 2B). Tumors initiated in all four loca-
tions were histologically similar and demonstrated features of GBM
(Figure 2C), including microvascular proliferation and extensive areas
of pseudopalisading necrosis (Figure 2C ). Platelet-derived growth
factor receptor injection with/or without PTEN loss (Figures 2, A
and C , and W1A) in the SVZ results in tumor formation in the
SVZ with extension into the ipsilateral frontal lobe and olfactory bulb,
suggesting that these tumors may migrate within the rostral migratory
stream in agreement with published literature [30]. In contrast, tumors
initiated at the right and left hemispheres produced tumors with dif-
fuse cortical involvement with no extension into the olfactory bulb and
no extension into the brainstem or cerebellum. In agreement with
human data [41,42], tumor formation resulting from cerebellar injec-
tions occurred at lower frequency compared with the other locations.
Nevertheless, high-grade tumors arose when PDGFB was injected
within the cerebellum with or without PTEN loss (Figures 2A and
W1, A and B). All tumors generated by these methods exhibited sim-
ilar proliferation rates as determined by immunostaining for PCNA
Ki67 and pH3, regardless of location (Figures 2D and W2).
Targeting PDGF to GFAP-Expressing SVZ Cells in Gtv-a
(GFAP-tv-a) Mice Leads to GBM Formation with Mixed
Oligoastrocytoma Histology
Most genetic alterations occurring in human gliomas result in signal
transduction abnormalities or disruption of cell cycle control pathways
[43]. The CDKN2A locus, which encodes p16Ink4A and p14ARF, is de-
leted in approximately 60% of human GBM [18], and the incidence of
Figure 2. RCAS/tv-a system allows generation of tumors in different locations of adult Ntv-amice overexpressing PDGFB in combination
with PTEN loss. (A) Kaplan-Meier survival curve of mice injected with PDGF in combination with PTEN loss (through coinjection with Cre)
in different locations of Ntv-a Ink4a-Arf−/−LPTEN mice demonstrated a tumorigenic advantage of the SVZ and the right and left hemi-
spheres versus the cerebellum. (B) Table showing the number of mice injected and tumor incidence (%) by PDGFB overexpression in
combination with PTEN loss in Ntv-a Ink4a-Arf−/−/LPTEN background. (C and D) Whole-mount H&Es and PCNA immunostaining for the
corresponding groups in Kaplan-Meier survival curve in the boxes corresponding to the color of each group. Statistical analysis was
performed to compare all the groups to the cerebellar group. Statistical significance is represented by star (Figure 3A). Statistical anal-
ysis between right and left hemispheres and SVZ shows the slight advantage of the right hemisphere compared with SVZ (*). All the
mice without obvious evidence of tumors were killed at 235 days after injection.
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p53 mutations is 31% in GBM and 48% in AA [44]. We used Gtv-a
transgenic mice (where the tv-a receptor is expressed on GFAP-positive
cells) in wt, p53−/−, Arf−/−, and Ink4a-Arf−/− backgrounds to model
the effect of cell cycle abnormalities in gliomas growing in different lo-
cations. As shown in Figure 3A, mice with tumors that were generated
in backgrounds with deletions of p53, Arf, or Ink4a-Arf had sig-
nificantly shorter latency compared with wt. Approximately 100% of
mice injected in Gtv-a p53−/−, Gtv-a Ink4a-Arf−/−, and Gtv-a Arf−/−
background develop GBM with oligoastrocytoma histologic finding,
whereas only 22% of Gtv-a mice in a wild type background develop
gliomas, all of which were low grade (Figure 3B). Tumors in Gtv-a
p53−/−, Gtv-a Ink4a-Arf−/−, and Gtv-a Arf−/− background are GBM,
composed of regions of more oligoastrocytoma and mixed astrocytoma
histologies (Figure 3C).
Imaging of Tumor Bearing Mice with Gli-luc Bioluminescence
and Magnetic Resonance Imaging
We recently reported the generation of a Gli-luc reporter mouse
that can be used to noninvasively image Gli activity in vivo. We dem-
onstrated that Gli activity, measured by luciferase bioluminescence
(BLI), correlates with tumor grade [45]. To investigate whether Gli
activity can also be used to image adult PDGF-induced gliomas, we
injected RCAS-PDGFB through the stereotactic technique into the
SVZ of Ntv-a Ink4aArf−/− Gli-luc adult mice. Similar to pediatric
tumors modeled with the RCAS/tv-a system, we noted increased bio-
luminescence at the tumor site in stereotactically injected adult mice.
Figure 4, A and B, shows an example of a BLI image of non–tumor-
and tumor-bearing mice correspondingly; these tumors can also be
imaged ex vivo as shown in the top right panel of Figure 4B. BLI
imaging of these mice is a useful tool to monitor tumor response to
therapy in vivo. To demonstrate shared characteristics between RCAS/
tv-a–generated tumors in adult mice and their human counterparts, we
imaged our tumor-bearing mice using magnetic resonance imaging
(MRI). Notably, these tumors share many imaging characteristics with
human GBM, as depicted by T2-weighted images of normal mouse
brain (Figure 4C) and a tumor-bearing mouse stereotactically injected
in the SVZ (Figure 4D). In summary, both MRI and BLI can be used
to monitor tumor presence and response to therapy in vivo in preclin-
ical trials.
Discussion
Mouse models of gliomas have been instrumental for investigating
the causative factors for this heterogeneous disease. Furthermore, re-
liable and accurate models are essential in the implementation of pre-
clinical studies to identify and validate new therapeutic strategies.
During the last decade, we have used the RCAS/tv-a technology
for modeling pediatric brain tumors, including pediatric gliomas.
However, these models have limitations, most notably that the small
Figure 3. RCAS/tv-a system allows generation of tumors in different genetic backgrounds of adult Gtv-amice by overexpressing PDGFB.
(A) Kaplan-Meier survival curve of tumor-bearing mice injected with PDGF in the SVZ in different genetic backgrounds of Gtv-a mice. (B)
Table showing the number of mice injected and tumor incidence (%) by PDGFB overexpression in different genetic backgrounds of Gtv-a
mice. p53, Arf, or Ink4a-Arf loss cooperate with overexpression of PDGFB to induce high-grade gliomas. In contrast, PDGFB injection in
Gtv-awt mice leads to low-grade glioma formation with low incidence. (C) H&E micrographs showing tumors generated in Gtv-a p53−/− or
Arf−/− or Ink4a-Arf−/− resemble mixed oligoastrocytoma histologic diagnosis. Scale bars, 74 μm. Statistical analysis reveals *** when
Gtv-a/Ink4a-Arf−/−, Gtv-a/p53−/−, and Gtv-a/Arf−/− are compared with Gtv-a wt; Gtv-a/Ink4a-Arf−/− versus Gtv-a/Arf−/− is not signifi-
cant; Gtv-a/p53−/− versus to Gtv-a/Arf−/− is **; Gtv-a/Ink4a-Arf−/− versus Gtv-a/p53−/− is *. All mice without obvious evidence of tu-
mors were killed at 146 days after injection.
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size of the mice at the time of tumor development poses significant
difficulties when performing treatment studies that require long-term
survival of the mice. In addition, several recent observations have in-
dicated that childhood malignant gliomas have important biological
characteristics that distinguish them from adult malignant gliomas
[22–24]. These factors led us to develop a novel RCAS/tv-a–based
model of adult gliomagenesis that could be used in parallel with
our preexisting pediatric models. The existence of these two models
now allows investigators to simultaneously compare the therapeutic
responses of pediatric and adult gliomas in future studies.
Our study also attempts to lend insight into the influence of loca-
tion on tumorigenic potential and tumor progression in an adult
mammalian system of gliomagenesis (Figure W2). It is known that
anatomic location in human gliomas influences prognosis and treat-
ment options [46,47]. We demonstrated that RCAS-PDGFB in-
jected into SVZ induced glioma formation in the SVZ and frontal
lobe with extension into the olfactory bulb, a very common location
for human gliomas [48]. We demonstrated that tumor incidence, la-
tency, and mortality do not differ when tumors are generated in dif-
ferent locations in the cerebral hemispheres, including the SVZ. By
contrast, tumors produced by cerebellar PDGFB overexpression are
localized to the cerebellum with extension into the brainstem and
occurred with lower incidence and with longer latency compared
with cerebral hemisphere and SVZ injections.
Targeting nestin-positive or GFAP-positive cells when injected in
the SVZ resulted in tumor formation with similar incidence and la-
tency. We further demonstrated that loss of tumor suppressors p53,
Arf, or Ink4a-Arf resulted in higher-grade tumors with shorter latency
and 100% incidence compared with their wild type counterparts, in
which only 22% of mice developed tumors, all of which are low
grade. Finally, because the location of injection resulted in character-
istic tumor locations in the mice, it is possible that a correlation exists
between tumors and their cells of origin in humans as well.
Adult mice bearing tumors generated by stereotactic injections
usually develop tumors when their weight range is 22 to 28 g, an
ideal weight for treating mice, making these mice excellent tools
for preclinical trials. BLI and MRI techniques further complement
this technique, allowing noninvasive monitoring of therapeutic re-
sponses. This model will allow investigators to interrogate the role
of tumor location, genetic background, and cell of origin (depending
which cell type we target originally, nestin− or GFAP−) in response to
therapy. We hope that data obtained from preclinical studies in these
mouse models will contribute to the development of individual tar-
geted therapies and accelerate the introduction of these therapies into
human clinical trials for gliomas.
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Figure W1. RCAS/tv-a system allows generation of tumors in different locations of adult Ntv-a mice by overexpressing PDGFB. (A) Kaplan-
Meier survival curve of mice injected with PDGF in different locations ofNtv-a Ink4a-Arf−/−mice demonstrated a tumorigenic advantage of
the SVZ and the right hemisphere versus the cerebellum. Statistical analysis was performed to compare all the groups to the cerebellar
group. Statistical significance is represented by star. Statistical analysis shows significant advantage of the right hemisphere and SVZ
compared with the cerebellum (**). (B) Table showing the number of mice injected and tumor incidence (%) by PDGFB overexpression
in Ntv-a Ink4a-Arf−/− background.
Figure W2. Tumors generated in different locations of adult Ntv-a mice overexpressing PDGFB in combination with PTEN loss show
similar proliferative ability. Representative images of immunostaining for Ki67 and pH3 (Ser10) show similar level of positive cells in
tumors generated by injecting PDGF in different locations of the brain. Scale bars, 74 μm.
